CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
V2R (Vasopressin 2 receptor)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02084797
NCT02084797N/ACompleted
CompareCT.gov

Revisiting the Human Sweat Gland - Does Arginine Vasopressin Modulate Sweat Sodium Concentration Via the V2 Receptor?

Oakland University·interventional·Posted Mar 12, 2014·Updated May 12, 2016

In Brief

A clinical study evaluating V2R (Vasopressin 2 receptor) for Electrolyte Imbalance and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This primary aim of this study was to critically assess whether or not sweat water content and sodium concentration were acutely regulated by dynamic changes in antidiuretic hormone (arginine vasopressin or AVP) acting on the Vasopressin 2 receptor (V2R) during exercise. Secondary aims were to evaluate running performance and core temperature to further characterize the role of AVP in the coordinated balance of fluid and temperature homeostasis during exercise. The primary hypothesis was that activation of the V2R in sweat glands would result in water reabsorption and fluid conservation during endurance exercise.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsElectrolyte Imbalance, Hyponatremia, Hypernatremia
CountriesUnited States
CollaboratorsGeorgetown University

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 12, 2014
Enrollment StartJun 1, 2011
Primary CompletionOct 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.3 years ago

Interventions

V2R (Vasopressin 2 receptor)drug

All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).